Skip to main content
Revolution Medicines, Inc. logo

Revolution Medicines, Inc. — Investor Relations & Filings

Ticker · RVMD ISIN · US76155X1000 LEI · 549300JU3X0LBCQ65892 US Professional, scientific and technical activities
Open in API
Filings indexed 749 across all filing types
Latest filing 2026-04-27 Proxy Solicitation & In…
Country US United States of America
Listing US RVMD

About Revolution Medicines, Inc.

https://www.revmed.com/

Revolution Medicines, Inc. is a clinical-stage precision oncology company dedicated to discovering and developing novel targeted therapies for cancers driven by the RAS pathway. The company's research focuses on creating innovative small molecule inhibitors that target key nodes within the RAS signaling cascade. Its pipeline is built on a platform designed to address various RAS mutations and associated proteins, aiming to provide transformative treatments for patients with RAS-addicted cancers, which have historically been difficult to treat.

Recent filings

Filing Released Lang Actions
DEF 14A - Revolution Medicines, Inc. (0001628171) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English
8-K - Revolution Medicines, Inc. (0001628171) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 14, 2026, reporting an equity offering and a convertible note offering by Revolution Medicines, Inc. It details underwriting agreements, offering prices, and expected proceeds. The document is a current report disclosing financing activities, specifically equity and convertible note offerings. It does not contain full financial statements or comprehensive financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement of a report publication, nor is it a certification or legal proceeding. The primary content is about capital raising activities and financing transactions. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7111 characters) supports it being a substantive filing rather than a brief announcement.
2026-04-16 English
424B5 - Revolution Medicines, Inc. (0001628171) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock and a concurrent convertible note offering by Revolution Medicines, Inc. It includes detailed terms of the offering, underwriting information, use of proceeds, risk factors, and other related disclosures. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering. It is not an annual report, earnings release, management discussion, or any other type of financial or governance report. It clearly fits the category of Capital/Financing Update, which covers updates on company fundraising and financing activities.
2026-04-15 English
424B5 - Revolution Medicines, Inc. (0001628171) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and prospectus for a convertible senior notes offering by Revolution Medicines, Inc. It includes detailed terms of the notes, interest, conversion features, redemption and repurchase provisions, ranking, underwriting details, risk factors, and legal disclaimers. The document is a formal offering document filed pursuant to Rule 424(b)(5), which is a prospectus supplement related to a securities offering. It is not a financial report, earnings release, management discussion, or any other type of corporate report. It is specifically related to capital raising and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to the clear nature of the document as a prospectus supplement for a debt offering.
2026-04-15 English
FWP - Revolution Medicines, Inc. (0001628171) (Subject)
Capital/Financing Update Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433 under the Securities Act. It contains detailed information about an offering of common stock and convertible senior notes, including pricing, underwriting details, use of proceeds, and terms of the notes. The document is a pricing term sheet supplementing preliminary prospectus supplements and registration statements. It is not a full financial report, earnings release, or management discussion, but rather a disclosure related to capital raising activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not a brief announcement or a report publication announcement. Hence, the classification is CAP with high confidence.
2026-04-15 English
8-K - Revolution Medicines, Inc. (0001628171) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Revolution Medicines, Inc. It reports topline results from a Phase 3 clinical trial and discusses forward-looking statements and plans to submit data to regulatory authorities. The document does not contain detailed financial statements or comprehensive financial analysis. It is an event-driven disclosure of clinical trial results and future regulatory plans, typical of an 8-K filing. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-04-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.